^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Suggested treatment regimens...CLL/SLL without del(17p)/TP53 mutation…Second-line and subsequent therapy…other recommended regimens...Zanubrutinib (for patients with intolerance or contraindication to other BTKi)